Butterfly Network (BFLY) Q2 2025: Gross Margin Hits 64% as Enterprise Pipeline Delays Shift Guidance
Butterfly Network delivered record quarterly revenue and all-time high gross margins, but macro-driven deal delays prompted a guidance reset. Enterprise and medical school deals remain active yet are taking longer to close, with management emphasizing cost discipline and product innovation to offset near-term uncertainty. Investors should watch for the impact of new software and home care pilots as Butterfly positions for long-term market leadership in handheld ultrasound.
Summary
- Enterprise Pipeline Friction: Larger hospital and medical school deals are active but experiencing lengthened sales cycles.
- Margin Expansion: Record gross margin highlights price and product mix leverage amid disciplined cost control.
- AI Platform and Home Care Launches: New software and care models could accelerate adoption and diversify revenue streams.
Performance Analysis
Butterfly Network posted its highest-ever quarterly revenue at $23.4 million, with gross margin reaching a record 64%. This performance was driven by higher average selling prices (ASP), international IQ3 launches, and increased chip sales to Octave partners, partially offset by lower US probe volumes. Product revenue rose 13% year-over-year, while software and other services revenue was flat as enterprise software growth offset softness in individual renewals.
Cash burn declined to $7 million for the quarter, reflecting ongoing cost discipline and a 24% improvement in adjusted EBITDA loss. International revenue grew 19%, demonstrating the early impact of geographic expansion, while US revenue was flat due to tough comparisons and delayed enterprise deals. Software and services now represent 29% of revenue, down from prior periods as hardware outpaced software growth with the IQ3 rollout.
- Product Mix Shift: Higher ASPs and chip sales boosted gross margin, while individual software renewals lagged.
- Geographic Expansion: International markets contributed outsized growth, validating Butterfly’s global strategy.
- Operating Leverage: Lower cash burn and improved EBITDA loss signal progress toward break-even, despite revenue guidance revision.
Despite strong execution on margin and cash flow, the near-term revenue outlook was revised downward as macro funding uncertainty extended enterprise deal timelines. Management emphasized that the pipeline remains intact, with delays rather than losses, and positioned the business to capitalize when conditions normalize.
Executive Commentary
"Our gross margins reached an all-time high at 64%, and our cash use was the lowest of any quarter at $7 million. Each quarter, we continued to deliver leverage as we marched to break even... we had expected to be further along in closing larger deals for additional growth. Those opportunities are still very much active while the sales cycle is being lengthened."
Joseph DeVivo, Chairman and Chief Executive Officer
"The 9% growth was primarily driven by higher average selling prices, the sale of semiconductor chips to partners in our octave business, and volume in our international markets... Our gross margin percentage was positively impacted by the higher average selling prices, the positive impact of the chip sales, as well as improvements in our software and services margin."
Heather Goetz, Chief Financial and Operations Officer
Strategic Positioning
1. Enterprise and Medical School Penetration
Butterfly is targeting large-scale deployments in top health systems and medical schools, aiming to embed its handheld ultrasound and software across institutions. While the pipeline is robust, macro funding uncertainty in healthcare is causing deal delays. Leadership asserts that no major deals have been lost, only deferred, and that Butterfly is pioneering new budget categories in hospitals that lack established handheld ultrasound procurement processes.
2. Software Platform Evolution with Compass AI
Compass AI, the next-generation software platform, is set to launch in the second half of 2025, promising to streamline documentation, automate workflow, and capture more reimbursement opportunities. This platform is designed to make enterprise deployments stickier and more scalable, providing a competitive edge in large-scale hospital and health system sales. The shift toward more automated, AI-driven software is expected to increase both pricing power and account penetration.
3. Butterfly Garden and Third-Party AI Ecosystem
Butterfly Garden, the company’s developer ecosystem, is entering its commercial phase with new FDA-cleared AI tools for cardiac and pulmonary scanning. This strategy enables clinicians without ultrasound training to leverage advanced diagnostics, expanding the addressable market for point-of-care ultrasound (POCUS) and driving recurring software revenue as more apps become available on the Butterfly platform.
4. Home Care Channel and Recurring Revenue Model
The home care pilot demonstrated a significant reduction in heart failure readmissions, validating Butterfly’s model of enabling non-specialist caregivers to perform scans, which are then remotely interpreted. This channel uses a per-member and per-scan fee model, offering a path to more predictable, recurring revenue compared to episodic probe sales. If scaled, even a single partner could generate $40 to $60 million in new revenue, according to management.
5. Octave Semiconductor and Technology Licensing
Octave, Butterfly’s semiconductor initiative, is generating both direct chip sales and strategic partnerships, including a collaboration with a generative AI company. This business line diversifies revenue and positions Butterfly to benefit from broader adoption of chip-based imaging across healthcare.
Key Considerations
Q2 marked a crossroads for Butterfly’s growth trajectory, as strong operational execution clashed with macro headwinds in healthcare funding and enterprise sales cycles. The company’s multi-pronged strategy—spanning hardware, software, AI, and new care settings—provides both resilience and optionality, but execution risk remains as the environment evolves.
Key Considerations:
- Deal Timing Risk: Enterprise and medical school deals are delayed, not lost, but timing remains unpredictable due to macro funding uncertainty.
- Software Stickiness Challenge: Individual subscription renewals are a headwind, while enterprise software is growing and expected to become more material as Compass AI launches.
- Home Care Scale Potential: Early pilots show strong clinical and financial impact, but commercial rollout and scaling remain to be proven.
- Cost Discipline: Management continues to prioritize cash preservation and margin expansion, supporting a path to break-even even as top-line growth moderates.
- Leadership Transition: The CFO transition is managed with continuity, but ongoing execution will be closely watched by investors.
Risks
The primary risk is prolonged macro uncertainty in healthcare funding, which could further delay enterprise and global health deals, impacting near-term revenue growth. Software renewal churn and slower adoption in new care settings add execution risk, while the competitive landscape, though not cited as a current headwind, remains dynamic. Regulatory and reimbursement changes could materially affect adoption rates and pricing power.
Forward Outlook
For Q3 2025, Butterfly guided to:
- Revenue of $20 million to $22 million
- Adjusted EBITDA loss of $8 million to $9 million
For full-year 2025, management lowered guidance to:
- Revenue of $91 million to $95 million
- Adjusted EBITDA loss of $32 million to $37 million (improved by $5 million despite revenue revision)
Management emphasized continued cost discipline and investment in growth areas, noting:
- Closing delayed large deals would be required to hit the high end of guidance
- Compass AI and home care commercialization are key catalysts for second-half performance
Takeaways
Butterfly’s Q2 results show the company’s ability to deliver margin and cash flow improvements even as top-line growth slows. Strategic bets on enterprise software, AI ecosystems, and home care could unlock new growth vectors, but the timing and scale of these opportunities remain uncertain.
- Margin Resilience: Record gross margin and lower cash burn provide a cushion for navigating near-term revenue volatility.
- Enterprise Sales Cycle Extension: Macro-driven delays in large deals are the central headwind, but pipeline remains active and competitive positioning is strong.
- Execution Watchpoint: Investors should monitor the rollout of Compass AI, home care partnerships, and the pace of international expansion for signs of reacceleration.
Conclusion
Butterfly Network’s Q2 delivered operational progress and strategic innovation, but macro headwinds forced a reset in revenue expectations. The company’s diversified growth levers provide upside optionality, but execution and macro clarity will dictate the timing and magnitude of future gains.
Industry Read-Through
Butterfly’s results reflect a broader trend in healthcare technology, where macro funding uncertainty is delaying large capital purchases and extending enterprise sales cycles. Vendors with strong recurring revenue models, AI-driven workflow enhancements, and global expansion strategies are better positioned to weather near-term volatility. The shift toward embedding AI in point-of-care devices and enabling non-specialists to deliver advanced diagnostics is likely to accelerate adoption industry-wide, but the path to mainstream scale still faces hurdles in funding, training, and institutional inertia.